Please ensure Javascript is enabled for purposes of website accessibility

Why Vertex Pharmaceuticals Stock Fell Today

By Prosper Junior Bakiny - Feb 2, 2021 at 4:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were not pleased with the company's latest quarterly update.

What happened?

Shares of biotech giant Vertex Pharmaceuticals (VRTX 3.19%) fell by as much as 6.7% on Tuesday and closed the day's trading session down by 6.2%. The company reported its financial results for the fourth quarter of fiscal year 2020, and investors were not impressed with the drugmaker's performance. 

So what

During its fourth quarter, which ended on Dec. 31, 2020, Vertex Pharmaceuticals recorded revenue of $1.6 billion, an increase of roughly 15% compared to the prior-year quarter. The biotech's top line also came in above the $1.58 billion analysts were expecting on average. Meanwhile, Vertex Pharmaceuticals' adjusted net income was $661 million, or $2.51 on a per-share basis. While the healthcare giant's adjusted net income soared by 49% year over year, its adjusted earnings per share (EPS) fell short of the $2.59 analysts were expecting on average.

man holding his head in panic.

Image source: Getty Images.

Perhaps this EPS miss explains the market reaction to Vertex Pharmaceuticals' earnings report, or maybe the 15% increase in the company's revenue wasn't enough to please its shareholders. Thanks to its monopoly in the market in treating the underlying causes of Cystic Fibrosis (CF), Vertex Pharmaceuticals has gotten investors used to dazzling top-line growth in recent years. The company projected that it would record revenue between $6.7 billion and $6.9 billion during 2021. Vertex Pharmaceuticals reported total revenue of $6.2 billion in 2020, a 49% increase compared to the previous fiscal year.

Now what 

In my view, investors should remain optimistic regarding Vertex Pharmaceuticals' future. The biotech company is still the undisputed leader in the market for CF drugs, and it has several exciting pipeline candidates it is working on, including a potential treatment for sickle cell disease it is developing with Crispr Therapeutics. In short, it is still worth buying shares of Vertex Pharmaceuticals, especially following today's dip. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$292.55 (3.19%) $9.05
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
CRSP
$66.96 (2.78%) $1.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.